Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
Hahn
Kevin A
KA
Gulf Coast Veterinary Specialists, Houston, TX 77027, USA. kevin_hahn@hillspet.com
Legendre
Alfred M
AM
Shaw
Neil G
NG
Phillips
Brenda
B
Ogilvie
Gregory K
GK
Prescott
Deborah M
DM
Atwater
Stephen W
SW
Carreras
Janet K
JK
Lana
Susan E
SE
Ladue
Tracy
T
Rusk
Anthony
A
Kinet
Jean Pierre
JP
Dubreuil
Patrice
P
Moussy
Alain
A
Hermine
Olivier
O
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides; D004283:Dog Diseases / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D004285:Dogs; D012515:Mast-Cell Sarcoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000662:veterinary*; D009367:Neoplasm Staging; D018579:Patient Selection; D010880:Piperidines; D011237:Predictive Value of Tests; D011725:Pyridines; D015996:Survival Rate; D017741:Survivors; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors
D000970:Antineoplastic Agents; D001549:Benzamides; D010880:Piperidines; D011725:Pyridines; D013844:Thiazoles; C526575:masitinib